C. diff might not originate from external transmission but rather from within the infected patient themselves.
Hospital staff dedicate significant effort to safeguard patients from infections during their hospital stay. Through practices ranging from hand cleanliness to the use of isolation rooms and stringent cleaning procedures, they strive to prevent infections. Yet, even with these measures, hospital-onset infections still occur—the most common of which is caused by the bacterium Clostridioides difficile, or C. diff, the culprit of almost half a million infections in the U.S. each year.
Surprising findings from a new study in Nature Medicine suggest that the burden of C. diff infection may be less a matter of hospital transmission and more a result of characteristics associated with the patients themselves.
The study team, led by Evan Snitkin, Ph.D. and Vincent Young, M.D., Ph.D., both members of the Departments of Microbiology & Immunology and Internal Medicine/Infectious Diseases at the University of Michigan Medical School and Mary Hayden, M.D. of Rush University Medical Center, leveraged ongoing epidemiological studies focused on hospital-acquired infections that enabled them to analyze daily fecal samples from every patient within the intensive care unit at Rush University Medical Center over a nine-month period.
"By systematically culturing every patient, we thought we could understand how transmission was happening. The surprise was that, based on the genomics, there was very little transmission."
Essentially, there was very little evidence that the strains of C. diff from one patient to the next were the same, which would imply in-hospital acquisition. In fact, there were only six genomically supported transmissions over the study period. Instead, people who were already colonized were at greater risk of transitioning to infection.
"Something happened to these patients that we still don't understand to trigger the transition from C. diff hanging out in the gut to the organism causing diarrhea and the other complications resulting from infection," said Snitkin.
Hayden notes this doesn't mean hospital infection prevention measures are not needed. In fact, the measures in place in the Rush ICU at the time of the study – high rates of compliance with hand hygiene among healthcare personnel, routine environmental disinfection with an agent active against C diff, and single patient rooms – were likely responsible for the low transmission rate. The current study highlights, though that more steps are needed to identify patients who are colonized and try to prevent infection in them.
Where did the C. diff come from? "They are sort of all around us," said Young. "C. diff creates spores, which are quite resistant to environmental stresses including exposure to oxygen and dehydration…for example, they are impervious to alcohol-based hand sanitizer."
However, only about 5% of the population outside of a healthcare setting has C. diff in their gut—where it typically causes no issues.
"We need to figure out ways to prevent patients from developing an infection when we give them tube feedings, antibiotics, proton pump inhibitors—all things which predispose people to getting an actual infection with C. diff that causes damage to the intestines or worse," said Young.
The team next hopes to build on work investigating the use of A.I. models to predict patients at risk of C. diff infection to identify patients who are likely to be colonized and who could benefit from more focused intervention.
Said Snitkin, "A lot of resources are put into gaining further improvements in preventing the spread of infections, when there is increasing support to redirect some of these resources to optimize the use of antibiotics and identify other triggers that lead patients harboring C diff and other healthcare pathogens to develop serious infections."
Reference: "Longitudinal genomic surveillance of carriage and transmission of Clostridioides difficile in an intensive care unit" by Arianna Miles-Jay, Evan S. Snitkin, Michael Y. Lin, Teppei Shimasaki, Michael Schoeny, Christine Fukuda, Thelma Dangana, Nicholas Moore, Sarah E. Sansom, Rachel D. Yelin, Pamela Bell, Krishna Rao, Micah Keidan, Alexandra Standke, Christine Bassis, Mary K. Hayden and Vincent B. Young, 18 September 2023, Nature Medicine.
DOI: 10.1038/s41591-023-02549-4
The study was funded by the National Institutes of Health and the Centers for Disease Control and Prevention.
News
Scientists Just Discovered a Cellular Survival System That Was Never Supposed To Exist
A surprising backup pathway allows cells to make a crucial amino acid when their primary machinery fails. For decades, biologists believed cells had only one way to access a molecule they cannot live without. New [...]
Artificial cells gain porous membranes, enabling lab reactions and drug release
Artificial cells created in the laboratory offer a wide range of potential applications. Until now, however, their membranes—unlike those of real cells—have been virtually impermeable. Researchers at the Max Planck Institute for Polymer Research, [...]
Popular Weight-Loss Drugs Like Ozempic Linked to Lower Breast Cancer Risk
Ozempic and similar weight-loss drugs were linked to a striking 30% reduction in breast cancer risk in a study of more than 110,000 women. Popular weight-loss and diabetes medications such as Ozempic, Wegovy, Mounjaro, [...]
Stanford Scientists Discover Explosive New Type of Immune Cell
Scientists studying the remarkable regenerative abilities of planarian flatworms have uncovered a previously unknown type of immune cell with an unusually destructive defense strategy. What if an immune cell could wipe out nearby threats [...]
Big Pharma-backed SonoThera sounds off with $125M series B for bubble-based genetic delivery
Bay Area biotech SonoThera is bubbling to a clinical boil after raising a $125 million series B with the backing of some of the biggest names in pharma. Vida Ventures led the raise, with the venture [...]
Joint initiative of 5 EU countries calls for ‘unified approach’ to pharma framework amid US drug pricing pressure
With drug pricing pressure building from the U.S., a healthcare-focused consortium of five European countries is calling for a “unified approach” to strengthen Europe’s pharmaceutical framework and access to innovative medicines. Belgium, the Netherlands, [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Molecular Manufacturing: The Future of Nanomedicine – New book from NanoappsMedical Inc.
This book explores the revolutionary potential of atomically precise manufacturing technologies to transform global healthcare, as well as practically every other sector across society. This forward-thinking volume examines how envisaged Factory@Home systems might enable the cost-effective [...]
NanoMedical Brain/Cloud Interface – Explorations and Implications. A new book from Frank Boehm
New book from Frank Boehm, NanoappsMedical Inc Founder: This book explores the future hypothetical possibility that the cerebral cortex of the human brain might be seamlessly, safely, and securely connected with the Cloud via [...]
New book from Nanoappsmedical Inc. – Global Health Care Equivalency
A new book by Frank Boehm, NanoappsMedical Inc. Founder. This groundbreaking volume explores the vision of a Global Health Care Equivalency (GHCE) system powered by artificial intelligence and quantum computing technologies, operating on secure [...]
UCLA Scientists Uncover a “Hidden Weakness” in Some of the World’s Deadliest Cancers
A new study has uncovered an unexpected vulnerability in some of the deadliest cancers. Researchers at UCLA have identified a previously hidden weakness in some of the most aggressive cancers, pointing to a possible new way [...]
AI-designed universal coronavirus vaccine clears first human trial
Key Takeaways Super-Antigen Technology: Uses AI and machine learning to analyze viral genomes, creating a single vaccine that targets essential features across entire virus families, including coronaviruses and Ebola. Human Trials & Safety: Phase [...]
Researchers Discover a Hidden Vitamin D Problem That Persists Year-Round
A new study suggests that some groups may not experience the expected seasonal boost in vitamin D levels, even during the sunniest months of the year. Many people assume that spending more time outdoors [...]
Researchers Solve the Mystery Behind a Billion-Dollar Dental Implant Disease
Researchers have uncovered why a common and costly dental implant infection often resists antibiotics. Dental implants have helped tens of millions of people regain a full set of stable, functional teeth, something traditional dentures [...]
Nanoparticles inspired by lung fluid improve therapies targeting respiratory system
The CIC biomaGUNE Center for Cooperative Research in Biomaterials has developed pulmonary surfactant nanoparticles (the blend of lipids and proteins that line the alveoli and enables breathing), which are encapsulated [...]
Scientists Finally Uncover How a “Forever Chemical” Causes Birth Defects
PFDA, a PFAS “forever chemical,” can cause craniofacial birth defects by disrupting retinoic acid regulation during fetal development, revealing the first clear molecular mechanism behind the link. Researchers have long linked perfluoroalkyl and polyfluoroalkyl substances (PFAS), [...]















